Safety & evidence

Are peptides
safe?

“Peptide” is a structure, not a safety category. Here is what is known, what is not, and what regulators in the US, UK and Australia say the risks are.

Short answerSafety & evidence · 8 min read · Updated 18 Nov 2026

Approved peptide medicines have safety data from controlled trials and a label listing known risks. Most research peptides have little or no controlled human safety data, and, between them, regulators in the US, UK and Australia point to four practical risks: unknown contents, immune reactions, unknown long-term effects and use without medical supervision.

Key takeaways

  • “Peptide” is a structural word: it covers hormones your body makes, approved prescription medicines and research compounds approved nowhere.
  • Approved peptide medicines such as semaglutide have known side effects, measured in large trials and printed on the label.
  • In a July 2026 briefing for its advisory committee, FDA staff concluded there is insufficient clinical safety information to characterise the safety profile of BPC-157. The FDA’s compounding safety-risk page says it has not identified any human exposure data for TB-500.
  • Between them, regulators in the US, UK and Australia point to four practical risks: not knowing what is in the vial, immune reactions, unknown long-term effects and use without medical supervision.
  • A small study with no reported problems cannot show that something is safe. It can only rule out problems that are common.

01Does being a peptide make something safe?

A peptide is a short chain of amino acids. That tells you how a molecule is built, not what it does or how risky it is.

Your body makes peptides: oxytocin is 9 amino acids long, glucagon 29. Some peptides are approved prescription medicines, such as semaglutide and tirzepatide. Some are cosmetic ingredients. Others, such as BPC-157 and TB-500, are research compounds not approved as medicines anywhere. Asking whether “peptides” are safe is like asking whether “pills” are safe. The answer depends on the molecule, the product, the standard it was made to, and how well it has been studied in people.

For the basics, start with what are peptides and types of peptides.

02Which peptides have safety data?

Approved peptide medicines have safety data from controlled trials and a label listing known risks. Most research peptides have little or no controlled human safety data.

KindExampleWhat is known about safety in peopleWhere that comes from
Approved medicineSemaglutide, tirzepatide (prescription medicines)Side effects were measured in large controlled trials and are listed on the label. The US label for Wegovy (semaglutide) carries a boxed warning: it causes thyroid C-cell tumours in rodents, and whether it does so in humans is unknown. It also lists warnings including acute pancreatitis and gallbladder disease.Phase 3 trials (STEP 1, 68 weeks; SURMOUNT-1, 72 weeks) and the FDA-approved labels (Wegovy, revised June 2026; Zepbound, revised August 2026)
Investigational drugRetatrutide (investigational; not approved anywhere)Adverse events were measured in controlled trials of the developer’s product, which no regulator has approved. In the phase 2 trial the most common adverse events were gastrointestinal and dose-related, and heart rate rose, peaking at 24 weeks.Phase 2 randomised trial, n=338, 48 weeks (NEJM, 2023)
Unapproved research compoundBPC-157, TB-500, injectable GHK-CuLittle or no controlled human safety data. FDA staff, July 2026 briefing, on BPC-157: “There is insufficient clinical safety information to characterize the safety profile.” On TB-500, FDA “has not identified any human exposure data.” On injectable GHK-Cu: possible immune reactions from aggregation and peptide-related impurities, and “limited data in humans.”FDA advisory committee briefing (July 2026) and FDA compounding safety-risk page (current as of 22 April 2026)

The grades behind “what is known” are explained in evidence grades.

03What risks do regulators name for unapproved peptide products?

Between them, regulators in the US, UK and Australia point to four practical risks with unapproved peptide products: unknown contents, immune reactions, unknown long-term effects and use without medical supervision.

1
Not knowing what is in the vial

“The biggest risks with unapproved peptide products are not knowing what is in the vial,” the TGA’s chief medical adviser said in September 2026, after a product sold as retatrutide was found to contain semaglutide and no retatrutide. The UK MHRA said in October 2026 that seized products “have not been assessed for safety, quality or effectiveness.” Victoria’s Chief Health Officer said the substance, concentration and possible contaminants in these products are unknown. Details: contamination and mislabeling.

2
Immune reactions

The FDA notes that peptides can provoke immune responses, with consequences that “may range from antibody responses with no apparent clinical manifestations to life-threatening and catastrophic reactions.” It says impurities and clumped peptide (aggregates) can raise that risk, and that subcutaneous and nasal routes carry more risk than oral or rectal ones. Victoria recorded 13 cases of anaphylaxis linked to unapproved peptides between July 2025 and October 2026; the advisory did not attribute them to a specific substance.

3
Unknown long-term effects

The published human studies of BPC-157 are, in FDA staff’s words, “of short duration” with “small sample sizes.” A 2026 narrative review in the Journal of the American Academy of Orthopaedic Surgeons concluded that validated pharmacokinetic and long-term safety data for BPC-157 are lacking.

4
Use without medical supervision

A 2026 case report described a woman in her mid-20s admitted to hospital with persistent nausea and vomiting after a series of injections of an unverified product reported to contain retatrutide, given in a wellness setting by someone without medical qualifications. She had not considered the injections to be medication; they came to light only after repeated questioning. The MHRA says anyone considering GLP-1 treatment should speak to a healthcare professional; Victoria advises discussing any use of unapproved peptides with a GP.

04Does “no side effects reported” mean a peptide is safe?

No. A small study with no reported problems cannot show that something is safe. Small studies can miss uncommon harms. A long-standing statistical rule, the “rule of three” (Hanley and Lippman-Hand, 1983), says that if nothing goes wrong in n people, the true rate of that problem could still be as high as about 3 ÷ n, at the usual 95% level of confidence. The shortcut is for larger groups; for very small ones the table gives the exact figure.

People studied, no problems seenThe problem could still affect up to…
2About 3 in 4 people (the exact figure; 3 ÷ n does not work for groups this small)
20About 1 in 7 people
300About 1 in 100 people
3,000About 1 in 1,000 people

That is why FDA staff, reviewing five small human studies of BPC-157, wrote that no serious adverse events “appear to have been reported” and, in the same paragraph, that the studies were short, small and gave “limited information on safety data.” Both halves matter.

05What we don't know

  • Long-term effects of any unapproved research peptide in people. We found no published long-term human study of BPC-157, TB-500 or injectable GHK-Cu (PubMed, November 2026).
  • How often harm occurs. Reporting is voluntary and incomplete. The FDA notes that compounding pharmacies under section 503A generally do not report adverse events to it, and people using research products may not tell their doctors.
  • Effects in specific groups, such as people with medical conditions, during pregnancy, or alongside other medicines. The small human studies were not designed to answer these questions.
  • Whether a clean vial changes the answer. A full lab report shows what was in the tested sample from that batch. It does not create safety data for the molecule.

Had a reaction to any product? Seek medical care first. Victoria’s Chief Health Officer put it plainly: people “should not delay seeking care because of concerns about how or where the product was obtained.” Then report it: FDA MedWatch (US), MHRA Yellow Card (UK) or the TGA (Australia).

Plain-English summary of public sources, checked 18 November 2026. Not medical or legal advice. For anything about your health, a doctor who knows you is the right call.

This content is educational. It is not medical advice and does not describe use in humans. 6AM Wellness products are sold for research use only and are not for human consumption. If you have a health condition, consult a licensed clinician who knows you.

RefSources

  1. US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee, 23–24 July 2026: BPC-157-related bulk drug substances. Advisory committee briefing, 2026. www.fda.gov/media/193343/download
  2. US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. FDA web page, content current as of 22 April 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  3. Novo Nordisk. WEGOVY (semaglutide) prescribing information. FDA-approved label via DailyMed, revised June 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2a…
  4. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med, 2023;389:514–526. PMID 37366315. pubmed.ncbi.nlm.nih.gov/37366315/
  5. Carbonell R. Patient suffers torn oesophagus after using unapproved peptide, prompting fresh warnings. ABC News (Australia), 14 September 2026. www.abc.net.au/news/2026-09-14/tga-peptide-warning-retatruti…
  6. Medicines and Healthcare products Regulatory Agency. Counterfeit weight loss pens worth £2 million seized by MHRA and West Mids Police. GOV.UK press release, 15 October 2026. www.gov.uk/government/news/counterfeit-weight-loss-pens-wort…
  7. Department of Health, Victoria. Anaphylaxis notifications linked to unapproved peptides. Health advisory 261027, 27 October 2026. www.health.vic.gov.au/health-advisories/anaphylaxis-notifica…
  8. Buzzi RM, Huber LC. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ Case Rep, 2026;19(10):e276106. PMID 42843917. pubmed.ncbi.nlm.nih.gov/42843917/
  9. Tham A, Hodgkins CW, Kennedy JG. Investigational peptides in orthopaedic practice: evidence, safety, and patient counseling for BPC-157, thymosin beta-4, and TB-500. J Am Acad Orthop Surg, 2026 (online ahead of print). PMID 42937313. pubmed.ncbi.nlm.nih.gov/42937313/
  10. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA, 1983;249(13):1743–1745. PMID 6827763. pubmed.ncbi.nlm.nih.gov/6827763/
  11. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med, 2021;384(11):989–1002. PMID 33567185. pubmed.ncbi.nlm.nih.gov/33567185/
  12. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med, 2022;387(3):205–216. PMID 35658024. pubmed.ncbi.nlm.nih.gov/35658024/
  13. Eli Lilly and Company. ZEPBOUND (tirzepatide) prescribing information. FDA-approved label via DailyMed, revised August 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-43…

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Is BPC-157 safe?

Nobody can say that it is. In a July 2026 briefing for its advisory committee, FDA staff concluded there is insufficient clinical safety information to characterise its safety profile; by their count, the human data are five small, short studies. See the BPC-157 research guide for the full evidence map.

Are peptides the same as steroids?

No. Peptides are chains of amino acids; anabolic steroids are built on a four-ring steroid structure. They are different classes of molecule with different evidence and rules.

Are collagen peptides the same as research peptides?

No. Collagen peptides are protein fragments sold as food and supplement ingredients. Research peptides are specific synthetic sequences sold with a research-use-only label. Evidence about one says nothing about the other.

Does a lab report make a peptide safe?

No. A lab report shows what was in the tested sample from a batch: identity, purity, amount and contaminants, if tested. It says nothing about what the molecule does in people.

Why do approved peptide medicines still have side effects?

Every medicine does. Approval means a regulator judged the benefits to outweigh the known risks for a specific use, based on controlled trials, and required those risks to be listed on the label.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page